3D-1001 is a next-generation selective COX-2 inhibitor with powerful anti-inflammatory/analgesic activity. Compared to conventional non-steroidal anti-inflammatory drugs (NSAID), 3D-1001 shows better safety, tolerance and efficacy. In October, 2020, 3D Medicines acquired the exclusive license from Haihe BioPharma (originally licensed by AskAt, Inc.), for the development and commercialization of 3D-1001 in analgesia indications in China. The Phase I clinical trial in China is on-going.
The advantages of selective COX-2 inhibitors in pain management
Conventional non-steroidal anti-inflammatory drugs (NSAIDs) act on both COX-1 and COX-2 to inhibit downstream prostaglandin E2 (PGE2), prostacyclin (PGI2), and thromboxane A2 (TXA2) pathways to exert their anti-inflammatory and analgesic effects. Because of their non-selective inhibition, traditional NSAIDs are often associated with serious adverse effects in addition to analgesia, with the incidence of gastric and duodenal ulcers 5 to 15 times higher than that in non-users. Selective COX-2 inhibitors can reduce gastrointestinal and cardiovascular side effects by specifically targeting the inflammatory-related PGE2 receptor pathway.
The clinical trials of 3D-1001
The oral solution of 3D-1001 has demonstrated better analgesic efficacy and safety in an ibuprofen-controlled Phase II clinical trial. The oral solid dosage is also being evaluated in Phase I clinical trial in China, and clinical trials related to analgesia will continue to be conducted.